MHRA sets out a more flexible regulatory path for AI-enabled medical devices
The UK’s Medicines and Healthcare products Regulatory Agency is moving its AI and MedTech agenda from strategy into operational planning, with a public update aimed at US industry leaders at AdvaMed 2026. The center of gravity is a more adaptive regulatory model for software and AI-enabled devices, one built to follow products across their lifecycle rather than freeze them at the point of first approval.
Jessica Paulsen, the agency’s Deputy Director for AI and Software, is scheduled to outline that approach at the conference, where the emphasis is on faster access without loosening patient protection. In practical terms, the MHRA is pushing toward a framework that can accommodate learning systems, software updates and iterative device modification without forcing every change into a rigid, one-time review structure.
The agency’s own 2030 strategy frames this as a response to the reality of modern digital medicine. AI tools do not behave like static hardware; they are updated, retrained and deployed in real clinical workflows where performance can shift as data, populations and use cases evolve. A regulatory system designed for fixed products struggles to keep pace with technology that keeps changing after launch.
Lifecycle regulation is becoming the central policy idea
The proposal reaches beyond broad rhetoric about innovation. It includes a modern framework for AI as a medical device, creation of a new MHRA Centre for AI and Digital Health, better device data and traceability, and expansion of reliance and recognition routes with trusted international regulators, including the FDA.
A single static approval may be too blunt for software that improves, drifts or expands in scope over time. In that setting, lifecycle regulation becomes less of a slogan and more of a safety requirement, because post-market monitoring, traceability and update oversight are the only tools capable of catching performance changes once a device enters everyday use.
The MHRA also points to a broader national shift. This month, the UK Government accepted all 44 recommendations from the NHS doctor-led independent National Commission into the Regulation of AI in Healthcare, backing a more proportionate, lifecycle-based approach. In regulatory language, proportionate does not mean permissive; it means matching scrutiny to risk, with deeper surveillance where clinical consequences are highest.
AI Airlock is already being used as a test bed
The agency is not waiting for legislation to catch up before building the system it wants. Its AI Airlock, described as a regulatory sandbox for AI-enabled medical devices, is already being used to test the approach in practice.
The setting matters. Sandboxes allow regulators and developers to examine how devices perform in controlled, real-world-like conditions before broad deployment. For AI, that can mean studying issues such as model drift, data bias, traceability of outputs and how performance changes when a tool is used by different clinicians or in different care pathways. The clinical significance is direct: an algorithm that behaves well in development can still underperform once it leaves the environment in which it was built.
Regional partnerships are extending that work. The MHRA is collaborating with NHS London and Manchester University NHS Foundation Trust, using real health settings to generate evidence that can shape future regulatory decisions. By pairing regulatory oversight with frontline NHS infrastructure, the agency is trying to narrow the gap between technical development and bedside reality.
Stronger FDA coordination is becoming a structural priority
International alignment is another major strand of the agenda. The MHRA is building new infrastructure around its relationship with the FDA through the MHRA-FDA Pioneer Programme, announced in June. Dedicated reciprocal liaison roles have been established within both agencies to support day-to-day collaboration, scientific exchange and coordination on emerging issues in medical devices and AI.
The move is important because AI-enabled devices increasingly enter global markets through parallel pathways. Divergent regulatory expectations can slow access, duplicate work and create uncertainty for developers trying to plan evidence generation. Closer cooperation does not erase independent decision-making, and both agencies will continue to act separately, but the structure is designed to reduce friction where scientific standards overlap.
A forthcoming Regional Deputy Director of US Partnerships, to be based in Washington, D.C., is intended to serve as the MHRA’s dedicated liaison officer to the FDA under that programme. The role is meant to deepen scientific and regulatory collaboration and strengthen links between UK and US life sciences ecosystems.
The agency has already signaled a broader goal: greater use of international reliance routes, including for devices already approved by the FDA. For medical technology developers, that could mean fewer redundant hurdles when evidence, surveillance and regulatory confidence already exist across trusted systems.
Post-market surveillance and traceability are moving up the agenda
Alongside AI policy and transatlantic cooperation, the MHRA is advancing wider medical device reform, including improved post-market surveillance and proposed legislative changes for a more responsive future framework. Those reforms speak to a familiar regulatory problem: premarket evidence can only answer so much, especially for devices that evolve after launch or are used across diverse patient groups.
In this context, stronger device data and traceability are not administrative extras. They are the mechanism by which regulators can identify failures, spot unusual performance patterns and determine whether a device still behaves as intended after software updates, wider rollout or changes in use.
The agency’s public direction is clear enough. It wants to support faster access to innovative technologies while strengthening patient safety, and it sees AI, post-market monitoring and cross-border coordination as parts of the same system rather than separate projects.
The remaining challenge is evidence that keeps pace with software
The central unresolved question is not whether AI will enter medicine; it already has. The harder task is building a regulatory model that can track a device after deployment without slowing beneficial innovation to a crawl or letting unsafe performance escape detection.
Real-world evidence will have to do more work than it does for many traditional devices. Software can change between reviews, and those changes can alter diagnostic performance, clinical workflow, or the relationship between a tool and the patients it serves. A sandbox can surface those issues early, but a durable system will require continuing surveillance, clearer standards for updates and a way to compare performance across jurisdictions.
For now, the MHRA is signaling that it wants the UK to be seen as a place where AI regulation is not merely reactive. The agency is positioning itself to shape a global standard for safe and agile regulation by 2030, while building the institutional machinery to make that ambition operational.
The next test will be whether the new architecture can deliver consistent oversight for devices that never really stand still.